2022 Revenues ($USD) : $59,283,000,000.00
2022 R&D spend : $13,548,000,000.00
2022 Number of Employees : 69,000
Fiscal Year End : 12/31/22
Leader : CEO Robert Davis

Founded in 1891, Merck saw a significant revenue lift in 2022. The company generated roughly $59 billion compared to $48.7 billion in 2021. In June, Kenilworth, N.J.–based Merck completed its spinoff of Organon, which specializes in reproductive medicine, contraception, psychiatry, hormone replacement therapy and anesthesia. In 2022, Merck's key revenue driver continued to be the immunotherapy therapy Keytruda, whose sales grew 22% to $20.9 billion. The company, however, is also facing increasing biosimilar competition for Keytruda. In the long term, the company has intensely focused on successfully navigating the headwind created by likely biosimilar competition to Keytruda at the end of the decade, noted Merck CEO Rob Davis. In 2022, other growth drivers included the human papillomavirus vaccine Gardasil and the company's animal health segment. —BB